Having trouble viewing this email? View it online here
Drug Discovery Today
ADMET, 10-11 July 2013
          WEBSITE           DIGITAL EDITION REGISTRATION           EVENTS           CONTACTS                                                          RSS   RSS feed

Drug Discovery Today ENews - June 2013

Editor's Choice

Leveraging HTS Traditionally, high-throughput screening (HTS) has been employed excessively during early drug discovery to identify compounds binding to a single target of interest. Nowadays, we experience the shift in research and development toward modulating agents and, more prominently, on small molecules acting simultaneously on a variety of receptors to remedy an indication or disease of interest. In order to increase the outcome of HTS, novel approaches had to be and in fact have been developed. Accomplishing these goals may be attended by more detailed considerations of biological pathways and deeper integration with computational resources. More

Have an article idea for Drug Discovery Today?

Free Research Articles to Download

Platforms for high-throughput screening of Wnt/Frizzled antagonists
28 May 2013
Signaling cascades initiated by Wnt lipoglycoproteins and their receptors of the Frizzled family regulate many aspects of animal development and physiology. Improper activation of this signaling promotes carcinogenic transformation and metastasis. Development of agents blocking the Wnt-Frizzled signaling is of prime interest for drug discovery. Despite certain progress no such agents are as yet brought to the market or even to clinical trials. One reason for these delays might be the use of suboptimal readout assays.

Drug Discovery Today: Webinars

Shifting from the single to the multitarget paradigm in drug discovery
28 May 2013
Increasing evidence that several drug compounds exert their effects through interactions with multiple targets is boosting the development of research fields that challenge the data reductionism approach.

The holistic integration of virtual screening in drug discovery
28 May 2013
During the past decade, virtual screening has come of age. In this article, Yusuf Tanrikulu, Bjorn Kruger and Ewgenij Proschak document the evolution and maturation of virtual screening from a rather exotic, stand-alone method toward a versatile hit and lead identification technology. Virtual screening campaigns have become fully integrated into drug discovery campaigns, evenly matched and complementary to high-throughput screening (HTS) methods.

For a full list of downloads/ white papers, please visit

Industry News

US Phase I study is extended to include systemic delivery of oncolytic virus. Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, is pleased to announce at ASCO that an on-going clinical study in the USA with its oncolytic virus, SEPREHVIR® (HSV1716), in children and young adults with non-CNS tumours has received permission from the regulatory authorities to enrol patients to receive intra-venous administration of the virus. More

Cancer Research UK launches trial for potential new drug to block cancer cells’ energy supply Cancer Research UK’s Drug Development Office (DDO) has launched a new clinical trial of a brand new type of experimental drug to treat a range of cancers. More

Small molecule could have big impact on cancer Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer. More

New data reinforces clinical importance of independent Alzheimer’s risk factor Manchester, Birmingham & Oxford, UK May 2013 – Cytox Limited, a UK company developing diagnostic and prognostic services for Alzheimer’s disease, announces the publication of new data using its blood-based phenoTOR™ assay technology. The data demonstrate the ability of the phenoTOR assay technology to assess the functional integrity of the mTOR pathway through analysis of lymphocytes and the relationship between this pathway and the development of Alzheimer’s disease pathology. The paper, published in Acta Neuropathologica Communications1, supports the development of the assay in the assessment of Alzheimer’s disease risk in patients. More


8th Protein Kinases in Drug Discovery Conference
Dates: 08 July 2013 until 09 July 2013
Location: Westin Copley Place Boston Hotel, Boston, MA, USA
Website: http://www.gtcbio.com/component/conference/?file=home&cn=8th...

Academic Drug Discovery Conference 2013
Dates: 09 October 2013 until 11 October 2013
Location: Nashville, Tennessee, USA
Website: http://www.addc2013.com/

Computational Aspects of High-Throughput Screening planning and analysis
Dates: 14 October 2013 until 16 October 2013
Location: EMBL Heidelberg, Germany
Website: http://www.embl.de/training/events/2013/CHI13-01/

For a full list of events and conferences, please visit

ddt button

Received this from a colleague? Sign up for your own regular copy of Drug Discovery Today Weekly.

This e-mail has been sent to you from Elsevier, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, registered in England with registered number 1982084.

You are receiving this e-mail because you are a registered subscriber of Drug Discovery Today. We respect your privacy and do not rent, sell or disclose your personal information to any non-affiliated third party without your consent, except as may be stated in our site's Privacy Policy: http://www.drugdiscoverytoday.com/legal/privacy/